Delcath Systems Inc (DCTH) Stock Price, Quote & News

Company Profile

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal...

Industry: Medical Devices

Sector: Healthcare

Phone: 212 489 2100

Fax: 212 489 2102

Website: www.delcath.com

Address:

566 Queensbury Avenue, Queensbury, United States

Playthegame06 Aug. 4 at 2:01 PM

$DCTH Looks like numbers have leaked!!

2 · Reply

GioW Aug. 4 at 9:57 AM

$DCTH I’ve noticed there are 37 centers taking referrals now on the Hepzato website. It was 36 not too long ago. Is it Yale New Haven that has been added?

1 · Reply

alexpitti Aug. 3 at 10:34 PM

$DCTH short interest is crashing into this report. i think the shorts have gone home. they enjoyed the vol in 2025

0 · Reply

LudwigVanBeethoven Aug. 3 at 8:56 PM

$DCTH mar-aug winner, bravo

1 · Reply

alexpitti Aug. 2 at 11:24 PM

good luck to everyone on delcath earnings. i would like to see a raising of guidance because q3 is looking better due to less seasonality, but you can't always get what you want $DCTH

1 · Reply

alexpitti Jul. 31 at 3:46 AM

$DCTH rp1 got a positive adcom vote which increases the chance of approval. But delcath competes with Rp2 which is still in clinical trial

0 · Reply

alexpitti Jul. 30 at 9:09 PM

$DCTH i think we fell in may and rose a bit back in june. the april data in this chart is 0, but the other one had like higher data. this is all similarweb so who knows

0 · Reply

alexpitti Jul. 30 at 8:57 PM

$DCTH hepzato web traffic increased in may and spiked further in june

1 · Reply

Humdinger1966 Jul. 30 at 8:22 PM

$DCTH Fascinating interview form Oct 2017 about the use of Chemosat in the UK: https://www.youtube.com/watch?v=x1J567xVylM

0 · Reply

alexpitti Jul. 30 at 6:34 PM

$DCTH hepzato website traffic up 233% to 1.2k in june

0 · Reply

Delcath Systems to Participate at the Canaccord Genuity 46th Annual Growth Conference

Jul 23, 2026, 4:01 PM EDT - 12 days ago

Delcath Systems to Host Second Quarter 2026 Earnings Call

Jul 16, 2026, 4:01 PM EDT - 19 days ago

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-07-13T11:20:52.000Z - 22 days ago

Delcath Systems price target raised to $17 from $16 at BTIG

2026-07-09T12:05:51.000Z - 26 days ago

Delcath Systems begins dosing in Phase 2 trial of Hepzato in breast cancer

Jul 9, 2026, 8:00 AM EDT - 26 days ago

Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer

2026-05-26T20:05:59.000Z - 2 months ago

Delcath Systems announces ASCO 2026 investigator initiated trials-in-progress

May 26, 2026, 4:01 PM EDT - 2 months ago

Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts

May 12, 2026, 8:00 AM EDT - 3 months ago

Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference

2026-05-07T14:11:04.000Z - 3 months ago

Delcath Systems presents new data on M-PHP at ESMO

2026-05-07T13:35:47.000Z - 3 months ago

Delcath Systems reports Q1 EPS (3c), consensus (9c)

2026-05-07T13:34:32.000Z - 3 months ago

Delcath Systems backs FY26 revenue view at least $100M, consensus $102.69M

May 7, 2026, 8:30 AM EDT - 3 months ago

Delcath Systems Earnings Call Transcript: Q1 2026

May 7, 2026, 8:30 AM EDT - 3 months ago

Delcath Systems Earnings release: Q1 2026

May 7, 2026, 8:30 AM EDT - 3 months ago

Delcath Systems Quarterly report: Q1 2026

May 7, 2026, 8:00 AM EDT - 3 months ago

Delcath Systems Reports First Quarter 2026 Results and Business Highlights

May 7, 2026, 7:00 AM EDT - 3 months ago

Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026

Apr 23, 2026, 8:30 AM EDT - 3 months ago

Delcath Systems to Host First Quarter 2026 Earnings Call

Apr 6, 2026, 8:30 AM EDT - 4 months ago

Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma

2026-04-02T14:44:15.000Z - 4 months ago

Delcath Systems management to meet with Craig Hallum

Apr 2, 2026, 8:00 AM EDT - 4 months ago

Delcath Systems Proxy statement: Proxy filing

Apr 2, 2026, 8:00 AM EDT - 4 months ago

Delcath Systems Proxy statement: Proxy filing

Apr 1, 2026, 8:30 AM EDT - 4 months ago

Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting

2026-03-03T13:43:26.000Z - 5 months ago

Delcath Systems publishes results from CHOPIN trial in The Lancet Oncology

Mar 3, 2026, 8:00 AM EST - 5 months ago

Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology

2026-02-26T18:26:15.000Z - 5 months ago

Delcath Systems price target lowered to $27 from $29 at Clear Street

2026-02-26T13:33:50.000Z - 5 months ago

Delcath Systems reports Q4 EPS (5c), consensus (3c)

2026-02-26T13:33:07.000Z - 5 months ago

Delcath Systems sees FY26 revenue at least $100M, consensus $110.56M

Feb 26, 2026, 8:30 AM EST - 5 months ago

Delcath Systems Earnings Call Transcript: Q4 2025

Feb 26, 2026, 8:30 AM EST - 5 months ago

Delcath Systems Annual report: Q4 2025

Feb 26, 2026, 8:30 AM EST - 5 months ago

Delcath Systems Earnings release: Q4 2025

Feb 26, 2026, 8:00 AM EST - 5 months ago

Delcath Systems Reports Fourth Quarter and Full Year 2025 Results

Feb 12, 2026, 8:00 AM EST - 6 months ago

Delcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call

Jan 27, 2026, 8:05 AM EST - 6 months ago

Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

2026-01-09T15:30:16.000Z - 7 months ago

Delcath Systems price target raised to $29 from $28 at Clear Street

2026-01-09T13:15:29.000Z - 7 months ago

Delcath Systems reports preliminary Q4 revenue $20.7M, consensus $19.99M

Jan 9, 2026, 8:05 AM EST - 7 months ago

Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

2025-12-31T13:15:08.000Z - 7 months ago

Delcath Systems publishes results from subgroup analyses of FOCUS study

Dec 31, 2025, 8:00 AM EST - 7 months ago

Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma

2025-12-03T21:05:29.000Z - 8 months ago

Delcath Systems announces publication of CHEMOSAT study

Dec 3, 2025, 4:01 PM EST - 8 months ago

Delcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma

2025-11-20T21:05:49.000Z - 9 months ago

Delcath Systems authorizes $25M buyback program

Nov 20, 2025, 4:01 PM EST - 9 months ago

Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program

2025-11-18T14:38:40.000Z - 9 months ago

Delcath Systems publishes review of Hepzato Kit

Nov 18, 2025, 8:00 AM EST - 9 months ago

Delcath Systems Announces Publication of Expert Narrative Review on Percutaneous Hepatic Perfusion for Liver Metastases from Uveal Melanoma

2025-11-13T14:21:28.000Z - 9 months ago

Delcath announces publication supporting early use of liver-directed therapy

Nov 13, 2025, 8:30 AM EST - 9 months ago

Delcath Systems Announces Publication of Real-World Evidence Supporting Early Use of Liver-Directed Therapy with PHP in Achieving Long-Term Survival for Metastatic Uveal Melanoma Patients

Nov 6, 2025, 4:01 PM EST - 9 months ago

Delcath Systems to Participate in Upcoming Investor Conferences

Nov 4, 2025, 8:30 AM EST - 9 months ago

Delcath Systems Earnings Call Transcript: Q3 2025

Nov 4, 2025, 8:30 AM EST - 9 months ago

Delcath Systems Quarterly report: Q3 2025

Nov 4, 2025, 8:30 AM EST - 9 months ago

Delcath Systems Earnings release: Q3 2025

Nov 4, 2025, 8:00 AM EST - 9 months ago

Delcath Systems Reports Third Quarter 2025 Results and Business Highlights

Oct 21, 2025, 8:30 AM EDT - 10 months ago

Delcath Systems to Host Third Quarter 2025 Earnings Call

Oct 20, 2025, 8:45 AM EDT - 10 months ago

Delcath Systems Transcript: Study Result

Oct 20, 2025, 8:45 AM EDT - 10 months ago

Delcath Systems Press release: Study Result

Oct 20, 2025, 7:00 AM EDT - 10 months ago

Delcath Systems Slides: Corporate Presentation

Oct 18, 2025, 4:15 PM EDT - 10 months ago

Delcath Systems Announces Preliminary Third Quarter 2025 Financial Results

Oct 18, 2025, 4:13 PM EDT - 10 months ago

Delcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary Endpoint

Sep 22, 2025, 4:01 PM EDT - 11 months ago

Delcath Systems Announces Investigator-Initiated CHOPIN Phase 2 Trial Presentation at ESMO 2025 Congress

Sep 10, 2025, 11:00 AM EDT - 11 months ago

Delcath Systems Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Aug 19, 2025, 8:30 AM EDT - 1 year ago

Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer

Aug 6, 2025, 8:30 AM EDT - 1 year ago

Delcath Systems Earnings Call Transcript: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 1 year ago

Delcath Systems Quarterly report: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 1 year ago

Delcath Systems Earnings release: Q2 2025

Aug 6, 2025, 8:00 AM EDT - 1 year ago

Delcath Systems Reports Second Quarter 2025 Results and Business Highlights

Jul 29, 2025, 4:01 PM EDT - 1 year ago

Delcath Systems to Participate at the Canaccord Genuity 45th Annual Growth Conference

Jul 23, 2025, 4:01 PM EDT - 1 year ago

Delcath Systems to Host Second Quarter 2025 Earnings Call

May 22, 2025, 10:00 AM EDT - 1 year ago

Delcath Systems Slides: Investor Presentation

May 22, 2025, 7:00 AM EDT - 1 year ago

Delcath Systems Issues Full Year 2025 Guidance

May 15, 2025, 4:30 PM EDT - 1 year ago

Delcath Systems to Participate at the Craig-Hallum 22nd Annual Investor Conference

May 9, 2025, 5:30 PM EDT - 1 year ago

Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 8, 2025, 8:30 AM EDT - 1 year ago

Delcath Systems Earnings Call Transcript: Q1 2025

May 8, 2025, 8:30 AM EDT - 1 year ago

Delcath Systems Quarterly report: Q1 2025

May 8, 2025, 8:30 AM EDT - 1 year ago

Delcath Systems Earnings release: Q1 2025

May 8, 2025, 7:30 AM EDT - 1 year ago

Delcath Systems Reports First Quarter 2025 Results and Business Highlights

Apr 28, 2025, 8:30 AM EDT - 1 year ago

Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer

Apr 24, 2025, 4:01 PM EDT - 1 year ago

Delcath Systems to Host First Quarter 2025 Earnings Call

Apr 9, 2025, 5:00 PM EDT - 1 year ago

Delcath Systems Announces Publication of Comparative Analysis from Randomized Portion of FOCUS Study in Metastatic Uveal Melanoma

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Delcath Systems Proxy statement: Proxy Filing

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Delcath Systems Proxy statement: Proxy Filing

Mar 24, 2025, 4:01 PM EDT - 1 year ago

Delcath Systems to Participate at the Canaccord Genuity Horizons in Oncology Virtual Conference

Mar 14, 2025, 4:01 PM EDT - 1 year ago

Delcath Systems, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mar 6, 2025, 8:30 AM EST - 1 year ago

Delcath Systems Earnings Call Transcript: Q4 2024

Mar 6, 2025, 8:30 AM EST - 1 year ago

Delcath Systems Annual report: Q4 2024

Mar 6, 2025, 8:30 AM EST - 1 year ago

Delcath Systems Earnings release: Q4 2024

Mar 6, 2025, 8:00 AM EST - 1 year ago

Delcath Systems Reports Fourth Quarter and Full Year 2024 Results

Feb 20, 2025, 8:30 AM EST - 1 year ago

Delcath Systems to Host Fourth Quarter and Full Year 2024 Earnings Call

Feb 14, 2025, 8:30 AM EST - 1 year ago

Delcath Systems Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines for the Treatment of Metastatic Uveal Melanoma

Jan 30, 2025, 7:06 PM EST - 1 year ago

Biotech walks a 'tightrope' amid unclear funding, regulations

ELVN IBB

Jan 28, 2025, 4:01 PM EST - 1 year ago

Delcath Systems to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Jan 13, 2025, 8:00 AM EST - 1 year ago

Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

Jan 3, 2025, 4:01 PM EST - 1 year ago

Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dec 30, 2024, 8:00 AM EST - 1 year ago

Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises

Dec 2, 2024, 8:30 AM EST - 1 year ago

Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer

Nov 8, 2024, 8:30 AM EST - 1 year ago

Delcath Systems Earnings Call Transcript: Q3 2024

Nov 8, 2024, 8:30 AM EST - 1 year ago

Delcath Systems Quarterly report: Q3 2024

Nov 8, 2024, 8:30 AM EST - 1 year ago

Delcath Systems Earnings release: Q3 2024

Nov 8, 2024, 8:00 AM EST - 1 year ago

Delcath Systems Reports Third Quarter 2024 Results and Business Highlights

Playthegame06 Aug. 4 at 2:01 PM

$DCTH Looks like numbers have leaked!!

2 · Reply

GioW Aug. 4 at 9:57 AM

$DCTH I’ve noticed there are 37 centers taking referrals now on the Hepzato website. It was 36 not too long ago. Is it Yale New Haven that has been added?

1 · Reply

alexpitti Aug. 3 at 10:34 PM

$DCTH short interest is crashing into this report. i think the shorts have gone home. they enjoyed the vol in 2025

0 · Reply

LudwigVanBeethoven Aug. 3 at 8:56 PM

$DCTH mar-aug winner, bravo

1 · Reply

alexpitti Aug. 2 at 11:24 PM

good luck to everyone on delcath earnings. i would like to see a raising of guidance because q3 is looking better due to less seasonality, but you can't always get what you want $DCTH

1 · Reply

alexpitti Jul. 31 at 3:46 AM

$DCTH rp1 got a positive adcom vote which increases the chance of approval. But delcath competes with Rp2 which is still in clinical trial

0 · Reply

alexpitti Jul. 30 at 9:09 PM

$DCTH i think we fell in may and rose a bit back in june. the april data in this chart is 0, but the other one had like higher data. this is all similarweb so who knows

0 · Reply

alexpitti Jul. 30 at 8:57 PM

$DCTH hepzato web traffic increased in may and spiked further in june

1 · Reply

Humdinger1966 Jul. 30 at 8:22 PM

$DCTH Fascinating interview form Oct 2017 about the use of Chemosat in the UK: https://www.youtube.com/watch?v=x1J567xVylM

0 · Reply

alexpitti Jul. 30 at 6:34 PM

$DCTH hepzato website traffic up 233% to 1.2k in june

0 · Reply

Happiness10cents Jul. 30 at 8:43 AM

$DCTH The poster from ESMO breast conference is old news..but it's good to hear these words " Not surprising that BCLMs respond to high dose Melphalan, which is an alkylating agent."

1 · Reply

brunoq14 Jul. 29 at 3:56 PM

$DCTH I see BlackRock has filed a 13G as a 5.3% owner (1.8M shares).

1 · Reply

RemitTekram Jul. 29 at 1:06 PM

$DCTH ST is fine....

1 · Reply

Jfree1121 Jul. 29 at 11:06 AM

$DCTH Stocktwits is shot...this is not up 8% pre market

2 · Reply

alexpitti Jul. 28 at 8:55 PM

$DCTH people say the most retarded shit on here. i keep getting surprised

0 · Reply

actuallysam Jul. 28 at 8:40 PM

$DCTH my theory would be people wanted an early report in July but if that was the case not long now, could be reporting in August makes think not a significant beat

1 · Reply

focafoca99 Jul. 28 at 8:40 PM

$DCTH attending the Canaccord Genuity 46th Annual Growth Conference on Aug 11, 2026 in Boston. https://www.rapidticker.com/news/dcth-delcath-systems-to-participate-at-ca1e5b

0 · Reply

mar99 Jul. 28 at 8:04 PM

$DCTH Wow this is so weak. I was crazy enough to think when we hit the new high around 13.70 recently we wouldn’t see the 11’s again. Need a good report next week.

1 · Reply

Playthegame06 Jul. 28 at 3:09 PM

$DCTH Is this a result of the AI meltdown? You would think a sector rotation is in order.

1 · Reply

alexpitti Jul. 27 at 10:46 PM

my best long ideas are $STXS $DCTH $ABEO $MIST $ISRG

2 · Reply

alexpitti Jul. 27 at 5:27 PM

$DCTH randomly crushed

0 · Reply

mar99 Jul. 27 at 3:20 PM

$DCTH Impressive how they drop this thing 50 cents from the morning high after a strong start on modest volume. Have to love the stock market BS.

0 · Reply

Market Cap	421.86M
Revenue (ttm)	85.23M
Net Income (ttm)	2.70M
EPS (ttm)	N/A
PE Ratio	1,204.00
Forward PE	N/A
Profit Margin	3.17%
Debt to Equity Ratio	0.00

Volume	441,340
Avg Vol	478,952
Day's Range	N/A - N/A
Shares Out	34.52M
Stochastic %K	97%
Beta	0.49
Analysts	Strong Sell
Price Target	$22.60